GPX4 is a potential biomarker and is associated with the diagnosis and treatment of diffuse large B lymphoma and B cell immune infiltration

Abstract

Abstract A large amount of evidence shows that the dysregulated expression of iron death plays a key role in cancer biology. GPX4 is a key gene for iron death and a risk factor for many cancers. However, the role of GPX4 in the genesis, development and immune process of diffuse large B lymphoma (DLBCL) has rarely been reported. The purpose of this study was to explore the significance of GPX4 in the diagnosis, prognosis and immune correlation of DLBCL. TNMplot, GSCA, TIMER 2.0, GEPIA and GEO databases were used to analyze the expression level of GPX4 and evaluate the prognosis. Metascape was used for enrichment analysis to study potential biological pathways. Finally, we used TIMER to explore the correlation between GPX4 and tumor infiltrating immune cells. GPX4 is expressed differently in various cancers. Compared with normal tissues, it is also significantly up-regulated in DLBCL tissues, and is related to the prognosis of DLBCL. In addition, enrichment analysis shows that GPX4 has a functional relationship with Glutathione peroxidase activity, Arachidonic acid metabolism, Leukotriene metabolic process, and Reactive oxygen species metabolic process. At the same time, we found that GPX4 has a significant correlation with CDCA7.